PSJ Web Site
J-STAGE
  Software Requirements
Microsoft Internet Explorer 5.01 or higher and Netscape Navigator 4.75 or higher are recommended.


J.Health Sci., 49(4), 267-272, 2003

-Minireview-

Therapeutic Approaches in Prion Disease

Naomi S. Hachiya,a, b Yuji Sakasegawa,a, b and Kiyotoshi Kaneko*, a, b

aDepartment of Cortical Function Disorders, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8502, Japan and bCore Research for Evolutional Science and Technology (CREST) of Japan Science and Technology Corporation, 4-1-8 Honcho, Kawaguchi-shi, Saitama 332-0012, Japan

Prion protein (PrP) exists in two different isoforms; a normal cellular isoform (PrPC) and an abnormal infectious isoform (PrPSc), the latter is a causative agent of prion disease such as Bovine Spongiform Encephalopathy (BSE, mad cow disease) and Creutzfeldt-Jakob disease (CJD). Great concern about variant CJD, which is caused by ingesting BSE-contaminated products, is also emerging and spreading over Japan since the first BSE-affected cattle was identified in September, 2001. The amino acid sequences of PrPC and PrPSc are identical, but their conformations are rather different; PrPC is rich in the non beta-sheet isoform while PrPSc is rich in the beta-sheet isoform. Our prion research focuses on further understanding such an unprecedented mechanism by identifying auxiliary factor(s) other than PrPC and PrPSc. These studies also help us to develop "therapeutics and prevention methods" for prion disease. Three major trials; genetic manipulation with dominant negative mutant PrPC gene working against a hypothetical host-specific factor, antibody therapy with anti-PrP antibodies which block PrPC-PrPSc binding, and PrPSc unfolding therapy with a novel-class molecular chaperone, are currently underway.